PharmaCyte Biotech, Inc. Filing for Femasys Inc.

PharmaCyte Biotech, Inc. (the "Reporting Person") has filed a Schedule 13G, amending and supplementing a previous Schedule 13D, concerning its beneficial ownership of Femasys Inc. (the "Issuer"). As of the filing date, the Reporting Person holds 4,932,825 shares of Common Stock, representing 7.87% ownership. This filing is necessitated by a change in beneficial ownership. Notably, on March 17, 2026, Joshua Silverman, an officer of the Reporting Person, resigned from the Issuer's Board of Directors. The Reporting Person certifies that the securities were not acquired or held for the purpose of influencing the control of the Issuer. The filing includes information regarding the number of shares beneficially owned and voting power. The Reporting Person also holds Series A warrants exercisable for an additional 4,237,288 shares of Common Stock, subject to a beneficial ownership limitation.